A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523933-24-00

Enrollment

110

Registered

2026-07-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Brief summary

Change from baseline to Week 52 in HbA1c (%)

Detailed description

Percent change from baseline to Week 52 in body weight, Change from baseline to Week 52 in body weight (kg), Achieved ≥ 5% weight loss from baseline at Week 52 and achieved HbA1c < 7% (53 mmol/mol) at Week 52, Achieved HbA1c ≤ 6.5% (48 mmol/mol) at Week 52, Achieved HbA1c < 7% (53 mmol/mol) at Week 52

Interventions

DRUGRybelsus 4 mg tablets

DRUGElecoglipron

DRUGRybelsus 1.5 mg tablets

DRUGRybelsus 9 mg tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline to Week 52 in HbA1c (%)	—

Secondary

Measure	Time frame
Percent change from baseline to Week 52 in body weight, Change from baseline to Week 52 in body weight (kg), Achieved ≥ 5% weight loss from baseline at Week 52 and achieved HbA1c < 7% (53 mmol/mol) at Week 52, Achieved HbA1c ≤ 6.5% (48 mmol/mol) at Week 52, Achieved HbA1c < 7% (53 mmol/mol) at Week 52	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 23, 2026